Alto Neuroscience Inc. has released a corporate presentation highlighting advancements in its clinical-stage precision medicine portfolio targeting central nervous system $(CNS)$ disorders. The company is advancing multiple product candidates using a biomarker-driven approach to patient identification, aiming to improve clinical outcomes in mental health conditions such as depression, schizophrenia, and bipolar disorder. The presentation outlines ongoing and planned clinical trials, including Phase 2 and Phase 3 studies for several candidates such as ALTO-207, ALTO-300, ALTO-100, and ALTO-101, with upcoming data readouts expected over the next two years. Alto reports having dosed over 800 patients across its studies and maintains a cash runway to support further development. You can access the full presentation through the link below.